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Background: There is increasing interest in astrocyte biology because astrocytes have been demonstrated to play
prominent roles in physiological and pathological conditions of the central nervous system, including
neuroinflammation. To understand astrocyte biology, primary astrocyte cultures are most commonly used because
of the direct accessibility of astrocytes in this system. However, this advantage can be hindered by microglial
contamination. Although several authors have warned regarding microglial contamination in this system, complete
microglial elimination has never been achieved.
Methods: The number and proliferative potential of contaminating microglia in primary astrocyte cultures were
quantitatively assessed by immunocytologic and flow cytometric analyses. To examine the utility of clodronate for
microglial elimination, primary astrocyte cultures or MG-5 cells were exposed to liposomal or free clodronate, and
then immunocytologic, flow cytometric, and gene expression analyses were performed. The gene expression
profiles of microglia-eliminated and microglia-contaminated cultures were compared after interleukin-6 (IL-6)
stimulation.
Results: The percentage of contaminating microglia exceeded 15% and continued to increase because of their
high proliferative activity in conventional primary astrocyte cultures. These contaminating microglia were selectively
eliminated low concentration of liposomal clodronate. Although primary microglia and MG-5 cells were killed by
both liposomal and free clodronate, free clodronate significantly affected the viability of astrocytes. In contrast,
liposomal clodronate selectively eliminated microglia without affecting the viability, proliferation or activation of
astrocytes. The efficacy of liposomal clodronate was much higher than that of previously reported methods used for
decreasing microglial contamination. Furthermore, we observed rapid tumor necrosis factor-α and IL-1b gene
induction in conventional primary astrocyte cultures after IL-6 stimulation, which was due to the activation of the
Janus kinase/signal transducer and activator of the transcription pathway in contaminating microglia.
Conclusions: Because contaminating microglia could result in erroneous data regarding the pro-inflammatory
properties of astrocytes, astrocyte biology should be studied in the absence of microglial contamination. Our simple
method will be widely applicable to experimental studies of astrocyte biology and provide clues for understanding
the role of astrocytes in neural development, function and disease.
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Astrocytes comprise the majority of cells in the central
nervous system (CNS). Although astrocytes were origin-
ally defined as gap fillers for neuronal networks, they
have been found to play prominent roles in normal CNS
functions, such as energy metabolism, neurotransmis-
sion, maintenance of blood–brain barrier, extracellular
ion homeostasis and cerebrovascular regulation [1,2]. In
pathological conditions, they also participate in neuroin-
flammation and tissue repair [2-5]. Much of this know-
ledge was obtained through experimental studies with
rodent primary astrocyte cultures. Because primary
astrocyte cultures are convenient and easy to establish,
they are most commonly used for assessing astrocyte
biology [6]. In brief, these cultures are prepared by dis-
sociation of cells of the dissected brain or spinal cord
and plating of the dissociated cells on dishes. With re-
gard to the detailed protocol for this method, several
minor modifications have been incorporated since the
original method was described [7-10]. However, these
modifications result in cultures in which astrocytes are
the predominant cells, but never comprise 100% of the
cells in these preparations (approximately 90% to 95%)
[6].
Microglia, the resident tissue macrophages of CNS, are
frequent contaminants of primary astrocyte cultures [6].
Microglial contamination has been often underestimated
because relatively small numbers of microglia were
observed in these cultures [6]. However, recent studies
suggested that the presence of microglia in primary
astrocyte cultures largely affects astrocyte responses
in vitro [11-13]. This will be especially problematic when
sensitive biochemical methods are employed, such as
high-through-put next-generation sequencing technology
[14]. In the CNS, microglia provides first line of host
defense despite that they comprise a relatively small pro-
portion of CNS cells. Microglia respond rapidly to patho-
logical alterations [15,16] and regulate responses of other
cells, including astrocytes [17-19]. Similarly, astrocytes
mediate responses, proliferation and activation of micro-
glia by releasing various cytokines or ATP [15,20]. Be-
cause these complex cell–cell interactions confound the
understanding of astrocyte function [6], astrocytes need
to be investigated in microglia-free conditions to accur-
ately assess their biology.
Clodronate belongs to a family of bisphosphonates and is
widely used to treat osteolytic diseases and osteoporosis be-
cause of its inhibitory effect on osteoclasts [21]. This drug is
known to induce apoptosis in macrophages or macrophage-
like cells [22] and is used to eliminate these cells in vivo
[23]. Because freely dissolved clodronate (free clodronate) is
a highly hydrophilic molecule that hardly crosses cellular
phospholipid membranes [21], liposome-mediated intracel-
lular delivery of clodronate has been developed formacrophage elimination [24]. Liposomes are artificially pre-
pared lipid vesicles consisting of concentric phospholipid
bilayers entrapping aqueous compartments that are used to
encapsulate hydrophilic molecules to dissolve them in aque-
ous solutions [25]. Liposome-encapsulated clodronate (lipo-
somal clodronate) is specifically phagocytized by
macrophages. After phagocytosis, lysosomal action disrupts
the fatty bilayers of the liposome, and free clodronate is
then released into the cell, causing irreversible functional
damage and apoptosis [26]. Selective elimination of macro-
phages by liposomal clodronate was reported in vitro
[22,27].
Since recent study demonstrated microglial death by
liposomal clodronate in the brain [28], we hypothesized
that liposomal clodronate can eliminate microglia in pri-
mary astrocyte cultures. In this study, we demonstrated
selective microglial elimination from primary astrocyte
cultures using liposomal clodronate without affecting the
viability, proliferation or activation of astrocytes. Further-
more, by comparing the gene expression profiles of
microglia-eliminated and microglia-contaminated pri-
mary astrocyte cultures after interleukin-6 (IL-6) stimu-
lation, we found that contaminating microglia induced
deceptive up-regulation of tumor necrosis factor alpha
(TNF-α) and interleukin (IL)-1β genes in conventional
primary astrocyte cultures through the activation of the
Janus kinase/signal transducer and activator of the tran-
scription (JAK/STAT) pathway, thus highlighting the im-
portance of microglial elimination from primary
astrocyte cultures. Using microglia-eliminated cultures,
functional aspects of astrocytes can be accurately studied
without complex interactions in response to specific
molecules. Our simple and useful method will be widely
applicable to experimental studies of astrocyte biology.
Material and methods
Preparation of primary astrocyte cultures
Conventional primary astrocyte cultures were prepared
from C57BL/6 mice as described previously [6,29,30]. In
brief, after removal of the meninges, postnatal day 3 (P3)
mouse brain tissues were minced and incubated in a
rocking water bath at 37 °C for 30 minutes in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad,
CA, USA) in the presence of 300 g/mL DNase I (Sigma-
Aldrich, St. Louis, MO, USA) and 0.25% trypsin (Sigma-
Aldrich). Enzyme-digested dissociated cells were tritu-
rated with 0.25% fetal bovine serum (FBS), washed and
centrifuged at 300 × g for five minutes. The pellet was
resuspended in DMEM, passed through a 30-μm nylon
mesh, washed, and centrifuged at 300 × g for five min-
utes. Following dilution with astrocyte-specific medium
(DMEM containing 10% FBS, 0.2 mML-glutamine, and
1% penicillin–streptomycin), the cells were plated on
poly-L-lysine–coated culture dishes at the density of
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a humidified CO2 incubator at 37 °C. Next, non-adherent
cells were removed, and fresh astrocyte-specific medium
was added. Adherent cells were maintained in astrocyte-
specific medium for seven days with a medium change
every two to three days [6]. For passage, monolayers
were rinsed with phosphate-buffered saline (PBS) and
then dislodged by trypsinization (0.25% trypsin and
0.02% ethylenediaminetetraacetic acid) for three minutes
at 37 °C and plated on poly-L-lysine-coated dishes at the
density of 5.0 × 104 cells/cm2. Passaged astrocyte cultures
between three and five weeks in vitro were used through-
out, unless otherwise specified. All experimental manipu-
lations were approved by the Ethics Committee on
Animal Experiment in the Faculty of Medicine, Kyushu
University, and conducted under the control of the
Guidelines for Animal Experimentation.
Conventional shake-off method
Primary astrocyte cultures were thoroughly agitated in
an orbital incubator shaker at 350 rpm and 37 °C for
12 h on Day 7 after their establishment. Immediately
after agitation, all cells suspended in the culture medium
were discarded, and attached cells were sub-cultured in
astrocyte-specific medium [6].
Preparation of liposomal clodronate
Liposomal clodronate was prepared as previously
described [25,31]. In brief, 4.30 mL phosphatidylcho-
line solution was added to 4.00 mL cholesterol solu-
tion in a 0.5 liter round bottom flask. The ethanol
was removed by low vacuum (58 mbar) rotary
(150 rpm) evaporation at 40 °C. The condensed etha-
nol was removed by aerating the flask three times.
The phospholipid film was dispersed in 20 mL clodro-
nate solution (for liposomal clodronate) or 20 ml PBS
(for empty liposomes) by gentle rotation at room
temperature. The suspension was kept at room
temperature for about two hours and then the solu-
tion was gently shaken. The suspension was put in a
50 ml plastic tube and sonicated in a water bath
(55 kHz) for three minutes. The suspension was kept
at room temperature for two hours. Before using the
liposomal clodronate, the non-encapsulated clodronate
was removed by centrifuging the liposomes at
24,000 × g and 10 °C for 60 minutes. The clodronate
liposomes will form a white band at the top of the
suspension, whereas the suspension itself will be
nearly clear. Carefully remove the clodronate solution
under the white band of liposomes with a 10 ml
pipet. The liposomes was resuspended in approxi-
mately 45 ml PBS and washed four to five times. The
final liposome pellet was resuspended in PBS and
adjusted to a final volume of 20.0 mL. The suspensionwas gently shaken before dispensing to achieve a
homogeneous distribution of the liposomes in suspen-
sion. Clodronate in PBS was used as the control for
liposomal clodronate, and clodronate disodium salt
(Calbiochem, La Jolla, CA, USA) was used as free
clodronate.
Microglial cell line culture
The MG-5 murine microglial cell line (kindly provided
by Dr Kohsaka S., Department of Neurochemistry,
National Institute of Neuroscience) was cultured as
described previously [32,33]. Conditioned medium
from the supernatant of murine astrocyte cell line A1
cells (kindly provided by Dr Kohsaka S.) cultured
overnight in DMEM containing 10% FBS and penicil-
lin-streptomycin (20 U/mL) was used as the culture
medium for MG-5 cells. The BV-2 murine microglial
cell line (kindly provided by Dr. Biber K., Department
of Medical Physiology, University Medical Center Gro-
ningen, University of Groningen) was cultured in
DMEM with 5% FBS, 2 mML-glutamine, and 1%
penicillin–streptomycin, as described previously
[34,35].
Immunocytologic analysis
Cultures were fixed for 15 minutes in cold 4% paraf-
ormaldehyde (PFA) in PBS at room temperature and
post-fixed in methanol at −20 °C for 15 minutes.
After being washed three times with PBS, fixed sam-
ples were permeabilized in 0.01% Triton-X in PBS for
30 minutes and blocked with 5% normal goat serum
for 1 h at 4 °C. Primary antibodies in the blocking so-
lution were applied overnight at 4 °C. Astrocytes were
identified using the rabbit anti-glial fibrillary acidic
protein antibody (anti-GFAP; 1:1,000; Dako Cytoma-
tion, Glostrup, Denmark, rat, mouse,), rat anti-GFAP
(1:1,000; Invitrogen), or mouse anti-GFAP(1:1,000;
Sigma-Aldrich). Microglia were identified using rabbit
anti-ionized calcium-binding adaptor molecule 1 (Iba1;
1:200; Wako, Osaka, Japan) or rat anti-CD68 (1:200,
Serotec, Oxford, UK). Rabbit anti-phosphorylated-
STAT3 (Tyr705) (anti-pSTAT3; 1:200, Cell Signaling
Technology, Danvers, MA, USA) were used to identify
the activation of JAK/STAT pathway. After rinsing,
samples were incubated with Alexa Fluor secondary
antibody conjugates for mouse, rabbit, or rat IgG
(1:200, Invitrogen) in blocking solution for 1 h at
room temperature. Nuclear counterstaining was per-
formed using Hoechst 33342 (Invitrogen). Proliferating
cells were identified using rabbit anti-Ki67 (1:1,000,
Novocastra, Newcastle, UK) or rabbit anti-phosphory-
lated histone H3 (Ser10) (p-His-H3; 1:1,000, Upstate/
Millipore, MA, USA). For propidium iodide (PI) stain-
ing, 0.1 mg/ml PI was added to the culture medium
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cent- labeled samples were coverslipped with fluores-
cent mounting medium (Dako Cytomation). Images
were captured using the BZ-9000 digital microscope
system (Keyence, Osaka, Japan) or an epifluorescent
microscope (BX51; Olympus, Tokyo, Japan) equipped
with a digital camera.
BrdU incorporation assay
The proliferation of microglia was examined by adding
50 μg⁄mL 5-bromo-20-deoxyuridine (BrdU) to the cul-
ture medium and incubating for 24 h. Following fixation,
samples were pre-treated with 2 N HCL at 37 °C for five
minutes. Rat anti-BrdU (1: 200; Abcam, Cambridge, UK),
mouse anti-GFAP, and rabbit anti-Iba1 were used to
identify proliferating astrocytes and microglia. Bound
antibodies were visualized using anti-rabbit, anti-mouse,
and anti-rat IgG secondary antibodies with Alexa Fluor
fluorescent conjugates.
Quantitative analysis
To quantify the number of BrdU-positive cells, anti-
BrdU–immunoreactive cells were counted using the BZ-
9000 digital microscope and BZII-Analyzer measurement
software (Keyence, Los Angeles, CA, USA). Algorithms
for counting the number of BrdU-positive cells were pro-
vided by Dynamic cell count BZ-H1C software (Key-
ence); these algorithms selectively count immunopositive
particles that range in size from 5 to 15 μm in both
dimensions (X and Y) and automatically eliminate spuri-
ous particles [19].
Flow cytometric analysis
Flow cytometric analysis was performed as previously
described [36]. In brief, confluent cultures were trypsi-
nized and resuspended in 10 mL of fresh astrocyte-
specific medium on the dish. After centrifugation at
300 × g and 4 °C for two minutes, the cell pellet was
resuspended in 10 mL medium. The resulting suspen-
sion was pelleted by centrifugation at 300 × g and 4 °C
for 2 minutes and then incubated on ice with fluores-
cent antibodies for 30 minutes. Samples were stained
phycoerythrin -Cy7–conjugated CD45 (eBioscience,
San Diego, CA, USA), fluorescein isothiocyanate-con-
jugated CD11b (eBioscience), PE-conjugated Gr-1
(eBioscience), and biotin-conjugated major histocom-
patibility complex class II (eBioscience). Allophycocya-
nin-conjugated streptavidin (eBioscience) was added to
label biotin-conjugated antibodies. All samples were
suspended in 500 μL fluorescence-activated cell sort-
ing (FACS) buffer (Hanks balanced salt solution, 2.5%
FBS, 0.1% NaN3) and analyzed at the same flow rate
and duration to allow comparisons among all samples
using a FACSAria II flow cytometer (BD Biosciences,San Jose, CA, USA). Data were analyzed using FACS-
Diva software (BD Biosciences).
Quantitative and semi-quantitative reverse transcription-
polymerase chain reaction (RT-PCR)
Total RNA was isolated from primary astrocyte cultures
using the RNeasy Mini kit (Qiagen, Hilden, Germany) or
from FACS-purified cells using the RNeasy Micro kit
(Qiagen) following the manufacturer’s protocol. For
cDNA synthesis, RT was performed using the Prime-
Script 1st strand cDNA Synthesis Kit (TaKaRa, Shiga,
Japan). Quantitative PCR (qPCR) was performed using
primers specific for the genes of interest [see Additional
file 1] and SYBR Premix Dimer Eraser (TaKaRa Bio) in
20-μL reactions. Data were normalized to glyceralde-
hydes-3-phosphate dehydrogenase expression (GAPDH).
RT-PCR was performed on a Thermocycler (Biometra,
Gottingen, Germany) and products were detected by
electrophoresis and SYBR Green I (Sigma-Aldrich).
Cell stimulation
Cells were stimulated with 50 ng/mL IL-6 (R&D Systems
Inc., Minneapolis, MN, USA) and 200 ng/mL soluble IL-
6 receptor (R&D Systems Inc.).
Statistical analysis
Statistical evaluations were performed using the Mann–
Whitney U-test. For multiple comparisons between
groups, the Kruskal–Wallis H test with Bonferroni’s post
hoc correction was used. P <0.05 was considered statisti-
cally significant. Data in graphs are presented as the
mean ± standard error of the mean (SEM).
Results
Contaminating microglia increase in number over time in
primary astrocyte cultures
We first examined change in the number of contaminat-
ing microglia in primary astrocyte cultures over time be-
cause their proliferative activities remain elusive in this
culture condition [6]. Dissociated cells from P3 mouse
brains were cultured in astrocyte-specific medium at
relatively low densities (5.0 × 104 cells/cm2) [6]. Astro-
cytes growing in primary monolayer cultures contained a
substantial number of contaminating microglia seven
days after preparation, as evidenced by the high levels of
Iba1 and CD68 (Figure 1A). Even after utilizing the con-
ventional shake-off method, many microglia were
observed in primary astrocyte cultures and these
remaining amoeboid microglia had multiple short spin-
ous processes (Figure 1B), suggesting strong adhesion of
these cells to culture dishes. When these primary astro-
cyte cultures were subcultured and maintained for
14 days without passage, the number of microglia grad-
ually increased with time, especially from 7 days after
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Figure 1 Quantitative analysis of microglial contamination in primary astrocyte cultures. (A) Triple immunostaining for primary astrocyte
cultures using Iba1 (red), CD68 (green), and GFAP (blue) antibodies. Scale bar, 100 μm. (B) High magnification of the remaining Iba1-positive
microglia after the shake-off method. Scale bar, 20 μm. (C) Triple immunostaining 4 and 14 days after the establishment of astrocyte primary
cultures. Scale bar, 200 μm. (D) Quantification of the number of contaminating microglia in passaged culture. (E) Triple immunostaining of
passaged culture using GFAP (green), BrdU (red), and Hoechst (blue) antibodies at 1, 4, and 14 days after seeding. Scale bar, 50 μm. (F) Changes in
the number of BrdU-positive proliferating astrocytes to the total number of astrocytes over time in passaged culture. (G) Triple immunostaining of
passaged culture using Iba1 (green) and BrdU (red) antibodies at 1, 4, and 14 days after seeding. Scale bar, 50 μm. (H) Changes in the number of
BrdU-positive proliferating microglia to total microglia over time in passaged culture. (I-J) Triple immunostaining of passaged culture using GFAP
(blue), CD68 (green), and Ki67 (red) antibodies at 1 and 10 days (I) and 14 days (J) after seeding. Scale bar, 50 or 200 μm. (K) The number of
GFAP-positive astrocytes and CD11b-positive microglia in the Ki67-positive proliferating cell population. (L) Immunostaining of primary astrocyte
cultures at 8 weeks after preparation showing Ki67-positive microglia. Scale bar, 200 μm. Inset shows high magnification image of Ki67-positive
microglia. (M) Flow cytometric analysis at one and eight weeks after culture preparation showed increased number of CD11b-positive microglia.
(N) Comparison of the number of the CD11b-positive population between one and eight weeks after preparation. *P <0.05, paired Student’s t-
test. Data are presented as the mean± SEM.
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potential of microglia in this culture. To assess their pro-
liferation in primary astrocyte cultures, we performed
the BrdU incorporation assay and Ki67 immunostaining.
The BrdU incorporation assay, which labeled S-phase
cells, demonstrated the presence of abundant proliferat-
ing cells in primary astrocyte cultures (Figure 1E-H).
Whereas there were large number of proliferating astro-
cytes four days after seeding (Figure 1E), a certain num-
ber proliferating microglia were observed in primary
astrocyte cultures (Figure 1G). Quantitative analysis
showed that the proliferation of astrocytes was most
prominent immediately after seeding and thereafter
gradually decreased (Figure 1E, F). In contrast, the prolif-
eration of microglia gradually increased over 14 days
(Figure 1G, H). Quantitative analysis of cells positive for
Ki67, a nuclear protein expressed in all phases of the cell
cycle, confirmed the extensive proliferative potency of
microglia (Figure 1I-K). Of note, the number of Ki67-
positive microglia was higher than that of Ki67-positive
astrocytes from seven days after seeding. We further
examined the temporal changes in the number of micro-
glia in astrocyte cultures for eight weeks with weekly
passages. The proliferative potential of microglia was
maintained after eight weeks of culture (Figure 1L), and
the number of contaminating microglia was significantly
higher at eight weeks after preparation than at one week
after preparation (Figure 1M, N). These results indicate
that the initially small number of contaminating micro-
glia could dramatically increase with time in primary
astrocyte cultures, thus highlighting the need for
complete microglial elimination from primary astrocyte
cultures.
Liposomal and free clodronate induce apoptosis of
microglia
Although free clodronate does not easily enter into
microglia because of difficulty in passage through cell
membranes, it slowly accumulates in cells that remain
in the surrounding medium [37]. In addition, recent
studies have suggested that free clodronate could in-
duce apoptosis of microglia [38-40]. Therefore, we
examined two forms of clodronate, free and liposomal,
for their ability to eliminate microglia using microglial
cell line MG-5 [32]. These cells were exposed to dif-
ferent concentrations of free or liposomal clodronate,
and PI staining was performed to evaluate MG-5 cell
death. Many PI-positive cells (indicating dead/dying
cells) were observed 24 h after clodronate exposure
(Figure 2A), and both forms of clodronate significantly
increased the number of PI-positive cells in a concen-
tration-dependent manner (Figure 2B). Three days
after exposure, both forms of clodronate significantly
reduced the number of MG-5 cells (Figure 2C, D).Although partial reduction was already observed using
5 μg/mL of liposomal clodronate, a nearly 10-fold
higher concentration of free clodronate was required
to produce a similar effect (Figure 2D). Most MG-5
cells were eliminated by 200 μg/mL of liposomal clo-
dronate and 2,000 μg/mL of free clodronate (Fig-
ure 2D). Analyses of repeated immunostaining of the
same sample confirmed that the efficacy of low-con-
centration liposomal clodronate was similar to that of
high-concentration free clodronate (Figure 2E). These
results indicate that both free and liposomal clodro-
nate can potentially eliminate microglia and that lipo-
somal clodronate more potently eliminates microglia
than free clodronate.
Liposomal clodronate selectively eliminates microglia
from primary astrocyte cultures
Similar to the results obtained in MG-5 cells, both forms
of clodronate completely eliminated microglia from pri-
mary astrocyte cultures after three days of treatment
(2,000 μg/mL of free clodronate and 200 μg/mL of lipo-
somal clodronate; data not shown). Because MG-5 cells
appear to be relatively resistant to apoptosis [32], pri-
mary microglia could be eliminated at concentrations
lower than those required for MG-5 cells. Therefore, we
attempted to determine the optimal concentration of
both forms of clodronate for selective microglial elimin-
ation from primary astrocyte cultures. Although flow
cytometric analysis showed that concentrations of free
clodronate required to eliminate primary microglia were
similar to those required to eliminate MG-5 cells
(2,000 μg/mL, three-day exposure), liposomal clodronate
eliminated microglia at concentrations lower than those
required to eliminate MG-5 cells (100 μg/mL, three-day
exposure) (Figure 3A, B). To assess whether free and
liposomal clodronate selectively eliminate microglia, we
examined the viability of microglia and astrocytes in pri-
mary astrocyte cultures after treatment with each clodro-
nate. PI-positive microglia were observed 24 h after
exposure to both forms of clodronate (Figure 3C),
whereas PI-positive astrocytes were rarely observed after
liposomal clodronate exposure. However, many PI-posi-
tive astrocytes were observed after exposure to free clo-
dronate (Figure 3C), and this type of clodronate
significantly decreased the number of astrocytes three
days after exposure (Figure 3D). These results indicate
that free clodronate but not liposomal clodronate signifi-
cantly affects the viability of astrocytes; therefore, only
liposomal clodronate was further examined for micro-
glial elimination. Next, the duration of exposure to lipo-
somal clodronate was assessed at the concentration
achieving complete elimination of microglia (100 μg/mL)
and 12 h of exposure to liposomal clodronate were suffi-
cient for microglial elimination (Figure 3E). These results
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exposure to both forms of clodronate. Scale bar, 200 μm. Data are presented as the mean± SEM.
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nates microglia from primary astrocyte cultures without
affecting the viability of astrocytes.
Liposomal clodronate did not affect the activation or
proliferation of astrocytes
We next determined whether liposomal clodronate-
mediated microglial elimination (100 μg/mL, 12 h)
affects the activation or proliferation of astrocytes. After
12 h of exposure to liposomal clodronate, the morpho-
logical features of astrocytes did not significantly change
and GFAP up-regulation was not observed (Figure 4A,
B). Nestin and vimentin, representative markers of astro-
cyte activation, were not up-regulated in any astrocytes
by exposure to liposomal clodronate (Figure 4A, B). To
confirm these results, CD11b-negative population after
12 h of exposure was purified using flow cytometer, and
qPCR was performed on FACS-purified CD11b-negative
population. The gene expression of Gfap and nestin was
not up-regulated in this population after exposure to
liposomal clodronate compared to that without liposomeclodronate exposure (Figure 4C). The proliferation of
cells was assessed by the BrdU incorporation assay and
Ki67 immunostaining. As shown in Figure 4D–G, the
number of Ki67- and BrdU-positive proliferating cells
among GFAP-positive astrocytes after exposure to lipo-
somal clodronate did not decrease compared to that
without liposomal clodronate exposure, suggesting that
100 μg/mL of liposomal clodronate did not inhibit the
proliferation of astrocytes. These results demonstrated
that liposomal clodronate does not affect the activation
or proliferation of astrocytes during microglial elimin-
ation from primary astrocyte cultures.
Liposomal clodronate eliminates microglia more
effectively than other methods
We compared the efficacy of liposomal clodronate to
that of previously reported methods in terms of micro-
glial elimination [6,13,41]. Seven days after preparation
of primary astrocyte cultures, microglial elimination was
performed via exposure to liposomal clodronate, flow
cytometric purification or the shake-off method, and the
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Figure 3 Liposomal clodronate effectively eliminates microglia from primary astrocyte cultures. (A, B) Flow cytometric analysis of primary
astrocyte cultures 3 days after exposure to free (A) or liposomal clodronate (B). The result indicated dramatic reduction in the CD11 positive (left)
and CD45int/CD11bpositive/Gr-1nega-int (right) populations in a concentration-dependent manner. Complete microglial elimination was achieved
using 2,000 μg/mL of free clodronate and 100 μg/mL of liposomal clodronate. (C) Triple immunostaining of primary astrocyte cultures 24 h after
exposure to each clodronate using GFAP (blue), CD68 (green), and PI (red) antibodies. There were many PI and GFAP double-positive cells after
exposure to free clodronate. Scale bar, 200 μm. (D) Quantification of the number of GFAP-positive cells three days after exposure to free or
liposomal clodronate (n = 5). The number of astrocytes significantly decreased after exposure to free clodronate (*P <0.05, Kruskal-Wallis test with
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http://www.jneuroinflammation.com/content/9/1/116contaminating ratio of microglia was determined using
flow cytometric analysis and immunostaining (Fig-
ure 5A–D). Flow cytometric analysis revealed that the
conventional shake-off method significantly reduced the
number of contaminating microglia, but a large number
still remained (13.1 ± 0.8%, Figure 5A, C). Although ef-
fective microglial elimination was achieved by flow cyto-
metric purification, a few microglia remained in the
purified astrocyte cultures (0.7 ± 0.2%, Figure 5A, C). In
contrast, no microglia were observed after exposure to
liposomal clodronate (Figure 5A, C). Quantification ofimmunostaining by digital image analysis confirmed the
efficacy of liposomal clodronate compared with the con-
ventional shake-off method and flow cytometric purifica-
tion (Figure 5B, D). These results were further confirmed
using RT-PCR and qPCR. Although gene expression of
Iba1, Cx3cr1, and Itgam (also known as Cd11b) was
observed in primary cells after conventional shake-off
and flow cytometric purification, their expression was
not detected after exposure to liposomal clodronate (Fig-
ure 5E, F). In addition, many PI-positive cells were
observed among the CD11b-negative population 24 h
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Figure 5 Comparison of microglia-decontamination methods. (A) Flow-cytometric assessment of enrichment of microglia in primary astrocyte
cultures. Microglia (CD45int/CD11bposi/Gr-1nega-int) were not observed in primary astrocyte cultures after exposure to liposomal clodronate. (B)
Immunostaining using Iba1 (red) and GFAP (green) antibodies. Scale bar, 50 μm. (C) The number of CD45-positive microglia in primary astrocyte
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http://www.jneuroinflammation.com/content/9/1/116after flow cytometric purification (Figure 5G), suggesting
that flow cytometric purification could affect the viability
of astrocytes. Because primary astrocyte cultures are typ-
ically used for several months after their preparation
[42,43], the microglia-eliminated cultures should be
maintained over time. Immunostaining and flow cyto-
metric analysis confirmed that the microglia-eliminated
culture was stably maintained for eight weeks after ex-
posure to liposomal clodronate (Figure 5H). These
results demonstrated that liposomal clodronate is opti-
mal for microglial elimination from primary astrocyte
cultures compared to other methods.
Delayed exposure to liposomal clodronate eliminates
microglia from primary astrocyte cultures
Many authors have established various types of genetic-
ally modified astrocytes [29]. To examine the availability
of delayed exposure to liposomal clodronate to these
established culture lines, unpurified astrocyte cultures
were exposed to liposomal clodronate eight weeks after
preparation, in which more microglia exist than those at
one week after the preparation (Figure 1L, M). Immuno-
cytologic analysis performed three days after treatment
revealed that 100 μg/mL of liposomal clodronate for
12 h eliminated microglia from unpurified cultures [see
Additional file 2]. These results indicate that this method
can eliminate microglia from already established astro-
cyte cultures.
Microglial contamination considerably affects the
analytical results of primary astrocyte culture
Finally, we compared the temporal gene expression
changes of pro-inflammatory cytokines after IL-6 stimu-
lation in microglia-contaminated and microglia-elimi-
nated primary astrocyte cultures. After 1 h of IL-6
stimulation, the nuclear translocation of pSTAT3 was
observed in astrocytes and microglia (Figure 6A, B), sug-
gesting activation of the JAK/STAT pathway in both
astrocytes and microglia. In contrast, only GFAP-positive
cells exhibited pSTAT3 accumulation in the nuclear re-
gion in microglia-eliminated astrocyte cultures (Fig-
ure 6C). qPCR demonstrated that IL-6, IL-1β and TNF-α
expression was significantly up-regulated in microglia-
contaminated cultures (Figure 6D). However, in micro-
glia-eliminated cultures, only IL-6 expression was signifi-
cantly up-regulated (Figure 6D). The time course of the
gene expression of TNF-α and IL-1β in conventional pri-
mary astrocyte cultures was similar to that in the BV-2
microglial cell line (Figure 6E). These results suggest that
rapid TNF-α and IL-1β gene induction in conventional
primary astrocyte cultures after IL-6 stimulation was
attributed to the activation of the JAK/STAT pathway in
contaminating microglia. To directly confirm these
results, conventional primary astrocyte cultures at 1 hafter IL-6 stimulation were sorted into CD11b-positive
and CD11b-negative populations by flow cytometer, and
the gene expression of pro-inflammatory cytokines in
each population was examined. qPCR analysis confirmed
that IL-6 expression was upregulated in the CD11b-
negative population and that TNF-α and IL-1β expres-
sion was upregulated in the CD11b-positive population
(Figure 6F). These results highlight the importance of
ensuring microglia elimination from astrocyte cultures to
precisely clarify astrocyte biology.
Discussion
Recent evidence has revealed the novel roles of astro-
cytes in CNS development and function [1-3,44,45].
Since astrocyte dysfunction has direct effects on neuro-
degenerative diseases, such as amyotrophic lateral scler-
osis, Alzheimer’s disease, and Huntington’s disease [46],
elucidation of astrocyte function under defined condi-
tions can facilitate the development of new treatment
strategies for CNS disorders [5,47,48]. Consequently,
there is increasing interest in understanding astrocyte
biology [1,5,48]. Although in vivo experiments have pro-
vided a considerable amount of information regarding
the mechanisms of action [29,49-51], the complex cell–
cell interactions and cytokine networks confound the in-
terpretation of these results. In this regard, in vitro
experiments are advantageous for investigating the biol-
ogy of these cells because of the direct accessibility to
components involved in a specific reaction. However, in
primary astrocyte cultures, this advantage has been hin-
dered by the difficulty in eliminating microglia and con-
trolling astrocyte–microglia interactions [6]. Many
authors have been concerned about the astrocyte culture
system because microglial contamination, even though it
was a small number of cells, could potentially affect
astrocyte responses [52-54], confound the interpretation
of results, and provide false information regarding astro-
cyte biology [6,11,12,55-58]. In fact, microglial contamin-
ation has been the cause of the incorrect assertion of
production of nitric oxide and apolipoprotein E by astro-
cytes [6,30,55,59,60]. Although there are several methods
to decrease the number of microglia in astrocyte cul-
tures, no method has completely eliminated microglia
from these cultures [6]. In this study, we demonstrated
that exposure to liposomal clodronate completely elimi-
nated microglia from primary astrocyte cultures, without
affecting the viability, proliferation, or activation of
astrocytes.
The most widely used technique for harvesting a single
population of glia is dependent on a mechanical shake-
off method based on the differential adherence proper-
ties of glia to the plastic of culture flasks/dishes [6,59];
astrocytes adhere more strongly to the plastic of culture
flasks/dishes than other glia. Although repetitive shaking
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Figure 6 Contaminating microglia rapidly produce TNF-α and IL-1β after IL-6 stimulation. (A–C) Triple immunostaining using GFAP (blue),
CD68 (green), and pSTAT3 (red) antibodies. Before IL-6 stimulation, pSTAT3 accumulation was rarely observed (A), but pSTAT3 accumulation was
observed in microglia-contaminated (B) and microglia-eliminated astrocyte cultures (C) 1 h after IL-6 stimulation. pSTAT3 accumulation was
observed in GFAP- and CD68-positive cells. Inset shows high magnification image of nuclear accumulation of STAT3 in microglia. Scale bar,
100 μm. (D) Time course of the gene expression of pro-inflammatory cytokines in microglia-contaminated or microglia-eliminated astrocytes after
IL-6 stimulation (n = 5). (E) Time course of the gene expression of pro-inflammatory cytokines in BV2 cells after IL-6 stimulation (n = 3). (F) Gene
expression of pro-inflammatory cytokines in FACS-purified CD11b-positive and CD11b-negative populations from conventional microglia-
contaminated primary astrocyte cultures 1 h after IL-6 stimulation (n = 3). *P <0.05, Kruskal-Wallis test with Dunn’s multiple-comparison test (D, E),
Mann–Whitney U test (F). Data are presented as the mean± SEM.
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http://www.jneuroinflammation.com/content/9/1/116reduces the contaminating microglia on top of the
monolayers, this method cannot achieve complete
microglia elimination [6], especially when glia are
strongly adherent to the plastic flasks/dishes or blan-
keted by astrocyte monolayers as shown in Figure 1B. As
another method to reduce microglial contamination,
anti-mitotic agents, such as 1-β-d-arabinofuranosylcyto-
sine (Ara-C) have been employed to eliminate proliferat-
ing microglia in primary astrocyte cultures [61,62].
However, it is reported that low concentrations of Ara-C
induces growth arrest and reactive responses in astro-
cytes while high concentrations kill astrocytes [63]. Be-
cause Ara-C is a potent S-phase–specific anti-tumor
agent, it is likely to affect astrocytes, especially proliferat-
ing astrocytes [55]. Moreover, this agent only eliminates
proliferating microglia and has little effect on non-prolif-
erating microglia. L-Leucine methyl ester (LME), a lyso-
somotropic agent, has also been used to eliminate
microglia, and effective reduction has been reported [56].
However, LME is toxic to astrocytes under some condi-
tions because of its free diffusion into cells [43,55]. In-
deed, it has been reported that LME unexpectedly
affected the adhesion capacity [55] and reactivity of
astrocytes [43,55].
Unlike previously used agents, liposomal clodronate
selectively eliminated microglia without affecting the via-
bility, proliferation or activation of astrocytes. This excel-
lent result was obtained because of a strategy based on
the different phagocytic activities of astrocytes and
microglia. Although a high concentration of free clodro-
nate affects the activities of cells via a non-specific extra-
cellular mechanism, such as increasing their membrane
permeability, clodronate is not a toxic molecule by itself
in the extracellular environment [25]. Liposomes are also
non-toxic and cannot freely move into cells [25]. There-
fore, liposome-encapsulated clodronate rarely affects
non-phagocytic cells [25]. In contrast, liposomal clodro-
nate is readily absorbed by phagocytic cells, resulting in
its rapid accumulation in the cytoplasm followed by the
induction of apoptosis. Many authors have demonstrated
that the liposome-mediated intracellular delivery of clo-
dronate selectively eliminated macrophages without in-
ducing toxicity in other cells [22,24,27,37]. Because
microglia are resident CNS immune cells that are func-
tionally equivalent to macrophages, their functions in-
clude phagocytosis and antigen presentation [64]. In the
CNS, they not only clear cellular debris from the area in
pathological conditions [53], but also continuously engulf
tissue components in normal physiological conditions
[16]. Indeed, their substantial phagocytic activity was
confirmed in vitro, but phagocytic activity was not
observed in astrocytes or other CNS cells [65].
Another strategy to reduce microglial contamination is
cell surface marker-based sorting [13,41]. However,positive astrocyte selection cannot be performed because
of the lack of a specific surface marker for astrocytes. In
addition, although this method can effectively reduce the
number of microglia from the primary astrocyte culture,
this method requires specialized machinery, such as flow
cytometric or magnetic cell sorting systems [13]. There-
fore, this strategy is excellent but lacks versatility, result-
ing in its limited use. In contrast, our method requires
only liposomal clodronate and, therefore, has broad util-
ity for analyzing astrocyte biology. Furthermore, liposo-
mal clodronate can eliminate human, rat and mouse
macrophage-like cells [22,25]. The number of contamin-
ating microglia in mouse primary astrocyte cultures is
higher than that in other species [6], indicating that our
method would be directly applicable to other species.
Neuroinflammation is a common pathological feature
of the CNS, and astrocytes are strongly implicated in the
initiation and development of neuroinflammation [13].
Therefore, many experimental studies are conducted to
elucidate the molecular responses of astrocytes during
neuroinflammation. In this study, we used microglia-
eliminated cultures and found that astrocytes produced
IL-6, but TNF-α and IL-1β, following the activation of
JAK/STAT pathway. Since the up-regulation of the IL-6
gene in astrocytes may be because of the STAT3 function
in a positive feedback loop to regulate gene expression,
STAT3 may not be directly related to the pro-inflamma-
tory properties of astrocytes. Conversely, all of these pro-
inflammatory cytokines were up-regulated after IL-6
stimulation of microglia-contaminated astrocytes cul-
tures due to the co-activation of contaminating micro-
glia. These findings indicate the significance of our
purified culture system to study neuroinflammatory
responses of astrocytes. Our method will allow under-
standing of the functional responses of astrocytes to dif-
ferent inflammatory cytokines/chemokines without the
complex effects of microglia and inflammatory networks
present during neuroinflammation.
Although our method permits selective assessment
for astrocytes, they are surrounded by microglia and
their response is modified by microglia in the CNS
[17]. Therefore, a detailed understanding of astrocyte-
microglia cross-talk is also important to elucidate the
disease onset and progression [44]. In this respect,
astrocyte cultures with microglia offer an advantage
over microglia-eliminated astrocyte cultures. In
addition, microglial response also needs to be assessed
without complex cell-cell interaction. In this study, we
used immortalized microglia cell line BV-2 to assess
microglial pro-inflammatory properties, their
responses may not entirely reflect microglial responses
in the CNS due to their partial failure in mounting
immune responses while also revealing spontaneous
activities [66]. Primary microglia will be useful to
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In the future, selective as well as interactive analysis
for primary glial cells will provide new clues to treat
CNS disease.
Conclusions
In summary, our method for eliminating microglia from
primary astrocyte cultures is simple, versatile and highly
efficient. Because liposomal clodronate did not alter the
activation or proliferation of astrocytes, these astrocyte
cultures are immediately available for experiment, ana-
lysis, or further subpopulation sorting or culturing. Our
method will help elucidate the reaction of astrocytes to a
specific substance and the functional roles of astrocytes
in physiological and pathological conditions, which will
provide clues to understanding the role of astrocytes in
neural disease, development and function. More careful
analyses of the many functions of astrocytes in micro-
glia-eliminated cultures is warranted to accurately under-
stand astrocyte biology.
Additional files
Additional file 1: Primer list
Additional file 2: Liposomal clodronate eliminates microglia from
long-term cultured astrocytes. At eight weeks after the preparation,
primary astrocyte cultures were exposed with liposomal clodronate. (A-B)
Double immunostaining using GFAP (green) and Iba1 (red) antibodies at
three days after exposure to liposomal clodronate. (A) 100 μg/mL of
liposomal clodronate completely eliminated microglia during three days
of exposure. (B) 100 μg/mL concentration of liposomal clodronate
completely eliminated microglia over 12 h of exposure duration. Scar bar,
500 μm.
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